Dr. Maltzman has three decades of oncology experience and has worked in the drug development space overseeing clinical, medical and regulatory affairs.
Dr. Maltzman will lead all activities related to IconOVir’s oncolytic virus therapeutics, including development, operations and medical affairs.
She most recently served as Genentech’s franchise head, vice president and global head of gastrointestinal and cancer immunotherapy.
Dr. Maltzman completed her internal medicine residency at the University of Chicago and her hematology/oncology fellowship at the Hospital of the University of Pennsylvania in Philadelphia.
“IconOVir’s unique modular approach to developing the next generation of oncolytic virus therapy has the potential to transform the landscape of cancer therapy and the lives of countless patients currently suffering from these diseases,” Dr. Maltzman said in an Oct. 10 IconOVir press release. “I look forward to bringing my experience as a medical oncologist and drug developer to IconOVir and supporting the expansion and acceleration of IconOVir’s pipeline to bring novel therapies to the patients that inspire our work.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.